SAN DIEGO — Harbor BioSciences Inc. said today it had reported encouraging data from its ongoing Phase I/IIa clinical trial with Apoptone for castration resistant prostate cancer — also referred to as hormone resistant prostate cancer — at the ASCO Genitourinary Cancers Symposium in San Francisco on March 6, 2010.
Go here to read the rest:
Harbor BioSciences Reports New Phase I/IIa Data at ASCO Symposium and Announces Plans to Advance Prostate Cancer … (GlobeNewswire via Yahoo!…
0 Responses to “Harbor BioSciences Reports New Phase I/IIa Data at ASCO Symposium and Announces Plans to Advance Prostate Cancer … (GlobeNewswire via Yahoo!…”